185 related articles for article (PubMed ID: 22373785)
1. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
[TBL] [Abstract][Full Text] [Related]
2. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
Lyu MA; Rai D; Ahn KS; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Gandhi V; Rosenblum MG
Neoplasia; 2010 May; 12(5):366-75. PubMed ID: 20454508
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG
Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624
[TBL] [Abstract][Full Text] [Related]
4. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
[TBL] [Abstract][Full Text] [Related]
5. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.
Nimmanapalli R; Lyu MA; Du M; Keating MJ; Rosenblum MG; Gandhi V
Blood; 2007 Mar; 109(6):2557-64. PubMed ID: 17119117
[TBL] [Abstract][Full Text] [Related]
6. Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.
Luster TA; Mukherjee I; Carrell JA; Cho YH; Gill J; Kelly L; Garcia A; Ward C; Oh L; Ullrich SJ; Migone TS; Humphreys R
PLoS One; 2012; 7(10):e47361. PubMed ID: 23056634
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.
Wen X; Lyu MA; Zhang R; Lu W; Huang Q; Liang D; Rosenblum MG; Li C
Mol Imaging Biol; 2011 Aug; 13(4):721-9. PubMed ID: 20686856
[TBL] [Abstract][Full Text] [Related]
8. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI
Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
11. Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1.
Zhang L; Jiang Y; Zheng Y; Zeng Y; Yang Z; Huang G; Liu D; Gao M; Shen X; Wu G; Yan X; He F
Leukemia; 2011 Feb; 25(2):331-40. PubMed ID: 21102426
[TBL] [Abstract][Full Text] [Related]
12. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
[TBL] [Abstract][Full Text] [Related]
13. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias.
Parameswaran R; Müschen M; Kim YM; Groffen J; Heisterkamp N
Cancer Res; 2010 Jun; 70(11):4346-56. PubMed ID: 20460528
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
[TBL] [Abstract][Full Text] [Related]
15. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
Shivakumar L; Ansell S
Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820
[TBL] [Abstract][Full Text] [Related]
16. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency.
Yuan X; Lin X; Manorek G; Howell SB
BMC Cancer; 2011 Feb; 11():61. PubMed ID: 21303546
[TBL] [Abstract][Full Text] [Related]
17. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
[TBL] [Abstract][Full Text] [Related]
18. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA
Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]